Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
TYGO Tigo Energy Inc
ERAS Erasca Inc
MEOH Methanex Corp
CADL Candel Therapeutics Inc
YECO Yulong Eco-Materials Ltd
ZVOI Zovio Inc
YEXT Yext Inc
ZNOG Zion Oil and Gas Inc
PM Philip Morris International Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada

Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Postmarket

Last Trade: Delayed
$0.2443

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.0043 (1.79%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $0.24

Day's Change: -0.0122 (-4.84%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.253

Day's Low: 0.235

Volume (Heavy Day) Volume: 2,759,488 10-day average volume: 2,199,328: 2,759,488

June 05, 2023
7:30 am ET	Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones --- Alex Nivorozhkin Ph.D. continues as Chief Scientific Officer - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and...(BusinessWire)
June 01, 2023
7:30 am ET	Cybin to Present at the Jefferies Healthcare Conference Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to...(BusinessWire)
May 30, 2023
5:46 pm ET	Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to...(BusinessWire)
May 24, 2023
7:30 am ET	Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial -- Parts A and B of Phase 1 study complete; Part C to determine safety, pharmacokinetic ("PK") and pharmacodynamic ("PD") of escalating doses of CYB004 in healthy volunteers -- --- Phase 1 topline safety and efficacy data expected in Q3 2023 - (BusinessWire)
May 09, 2023
7:30 am ET	Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial --- CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT - --- Phase 1 topline data expected in Q3 2023 - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a...(BusinessWire)
April 28, 2023
8:00 am ET	Cybin to Participate at the 26th Annual Milken Institute Global Conference Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced...(BusinessWire)
April 12, 2023
7:30 am ET	Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Postmarket

Change Since Close

Market Hours